Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coal tar

This article was originally published in The Tan Sheet

Executive Summary

FDA finds "no adequate basis to change the status of coal tar-containing drug products for the treatment of dandruff, seborrheic dermatitis and psoriasis from OTC to prescription or to require additional warning statements on product labeling," agency says in Feb. 22 response to Occupational Knowledge International's citizen petition seeking Rx-only sales of the ingredient. California Prop 65 litigation had been stayed pending FDA's determination
Advertisement

Related Content

OTC Coal Tar Skin Cancer Causation Data Lacking - FDA
OTC Coal Tar Skin Cancer Causation Data Lacking - FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS092221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel